23465-76-1

Basic information

• Product Name: CAROVERINE
• Synonyms: 1-[2-(Diethylamino)ethyl]-3-[(4-methoxyphenyl)methyl]quinoxalin-2(1H)-one;Spasmium;1-(2-(Diethylamino)ethyl)-3-(p-methoxybenzyl)-2(1H)-quinoxalinone;1-Diethylaminoethyl-3-(p-methoxybenzyl)quinoxalone-2;55750-05-5 (Mono-hydrochloride);Caroverina;Caroverina [inn-spanish];Caroverinum
• CAS NO: 23465-76-1
• Molecular Formula: C₂₂H₂₇N₃O₂
• Molecular Weight: 365.47
• Mol File: 23465-76-1.mol

Chemical Properties

• Melting Point: 69°
• Boiling Point: bp0.01 202°
• Flash Point: 269°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 5.81E-11mmHg at 25°C
• Refractive Index: 1.577
• PKA: 9.52±0.25(Predicted)
• CAS DataBase Reference: CAROVERINE(CAS DataBase Reference)
• NIST Chemistry Reference: CAROVERINE(23465-76-1)
• EPA Substance Registry System: CAROVERINE(23465-76-1)

Safety Data

• Hazardous Substances Data: 23465-76-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Caroverine is used as a treatment for inner ear diseases, specifically tinnitus, due to its ability to act as a calcium channel blocker and an antiglutamatergic drug. This dual action helps alleviate the symptoms and underlying issues associated with tinnitus, providing relief to patients suffering from this condition.
Used in Neurological Applications:
In the field of neurology, Caroverine is used as a therapeutic agent for managing tinnitus and other inner ear-related disorders. Its calcium channel blocking and antiglutamatergic properties contribute to the regulation of neural activity, which can help reduce the perception of ringing or buzzing sounds in the ears, a common symptom of tinnitus.
Used in Research and Development:
Caroverine is also used in research and development for the study of inner ear diseases and the development of new treatments for tinnitus and other related conditions. Its unique properties as a calcium channel blocker and an antiglutamatergic drug make it a valuable compound for exploring novel therapeutic approaches and understanding the underlying mechanisms of inner ear disorders.

InChI:InChI=1/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3

Upstream product

• 1610961-27-7 4-(2-chloroethyl)-2-(4-methoxybenzyl)-3-oxo-3,4-dihydroquinoxaline 1-oxide 
• 122-98-5 2-Anilinoethanol 
• 1610961-31-3 1-(2-chloroethyl)-3-(4-methoxybenzyl)quinoxalin-2(1H)-one 
• 1610961-35-7 1-(2-iodoethyl)-3-(4-methoxybenzyl)quinoxalin-2(1H)-one 
• 109-89-7 diethylamine 
• 935-06-8 N-(2-chloroethyl)aniline 
• 1610961-19-7 N-(2-chloroethyl)-2-cyano-N-phenylacetamide 
• 1610961-20-0 4-(2-chloroethyl)-2-cyano-3-oxo-3,4-dihydroquinoxaline 1-oxide 

Relevant articles and documents

A diversity-oriented synthesis of caroverine derivatives via TEMPO-promoted aerobic oxidative C-N bond formation

A concise method has been developed for the synthesis of caroverine and its derivatives. The quinoxalinone scaffold of these compounds was constructed via the tandem nitrosation/aerobic oxidative CN bond formation reaction of N-(2-chloroethyl)-2-cyano-N-phenylacetamide, followed by sequential Grignard, Finkelstein and nucleophilic substitutions reactions to give several different derivatives. Herein, we describe the development of this strategy in terms of the optimization of each step as well as the effect of different additives on the individual reactions.